Janet J Maguire

List of Publications by Year
in descending order

125	8,436	44069	46799
papers	citations	48 h-index	89 g-index

129	129	129	11259
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Endothelin-1 is increased in the plasma of patients hospitalised with Covid-19. Journal of Molecular and Cellular Cardiology, 2022, 167, 92-96.	1.9	19
2	Apelin is expressed throughout the human kidney, is elevated in chronic kidney disease & associates independently with decline in kidney function. British Journal of Clinical Pharmacology, 2022, 88, 5295-5306.	2.4	3
3	Plasma levels of apelin are reduced in patients with liver fibrosis and cirrhosis but are not correlated with circulating levels of bone morphogenetic protein 9 and 10. Peptides, 2021, 136, 170440.	2.4	7
4	Human embryonic stem cell-derived cardiomyocyte platform screens inhibitors of SARS-CoV-2 infection. Communications Biology, 2021, 4, 926.	4.4	11
5	The therapeutic potential of apelin in kidney disease. Nature Reviews Nephrology, 2021, 17, 840-853.	9.6	39
6	Ghrelin receptor in GtoPdb v.2021.3. IUPHAR/BPS Guide To Pharmacology CITE, 2021, 2021, .	0.2	0
7	THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G proteinâ€coupled receptors. British Journal of Pharmacology, 2021, 178, S27-S156.	5.4	337
8	In vitro metabolism of synthetic Elabela/Toddler (ELA-32) peptide in human plasma and kidney homogenates analyzed with mass spectrometry and validation of endogenous peptide quantification in tissues by ELISA. Peptides, 2021, 145, 170642.	2.4	2
9	Differential expression in humans of the viral entry receptor ACE2 compared with the short deltaACE2 isoform lacking SARS-CoV-2 binding sites. Scientific Reports, 2021, 11, 24336.	3.3	12
10	Apelin peptides linked to antiâ€serum albumin domain antibodies retain affinity in vitro and are efficacious receptor agonists in vivo. Basic and Clinical Pharmacology and Toxicology, 2020, 126, 96-103.	2.5	14
11	Genes encoding ACE2, TMPRSS2 and related proteins mediating SARS-CoV-2 viral entry are upregulated with age in human cardiomyocytes. Journal of Molecular and Cellular Cardiology, 2020, 147, 88-91.	1.9	21
12	A rational roadmap for SARSâ€CoVâ€2/COVIDâ€19 pharmacotherapeutic research and development: IUPHAR Review 29. British Journal of Pharmacology, 2020, 177, 4942-4966.	5.4	61
13	Advances in therapeutic peptides targeting G protein-coupled receptors. Nature Reviews Drug Discovery, 2020, 19, 389-413.	46.4	162
14	Genetic dysregulation of endothelin-1 is implicated in coronary microvascular dysfunction. European Heart Journal, 2020, 41, 3239-3252.	2.2	73
15	The G Protein Biased Small Molecule Apelin Agonist CMF-019 is Disease Modifying in Endothelial Cell Apoptosis In Vitro and Induces Vasodilatation Without Desensitisation In Vivo. Frontiers in Pharmacology, 2020, 11, 588669.	3.5	7
16	Kisspeptin receptor (version 2020.4) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide To Pharmacology CITE, 2020, 2020, .	0.2	0
17	THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G proteinâ€coupled receptors. British Journal of Pharmacology, 2019, 176, S21-S141.	5.4	519
18	Apelin-36-[L28A] and Apelin-36-[L28C(30kDa-PEG)] peptides that improve diet induced obesity are G protein biased ligands at the apelin receptor. Peptides, 2019, 121, 170139.	2.4	10

#	Article	IF	Citations
19	A novel cyclic biased agonist of the apelin receptor, MM07, is disease modifying in the rat monocrotaline model of pulmonary arterial hypertension. British Journal of Pharmacology, 2019, 176, 1206-1221.	5.4	32
20	BS49â€…Human embryonic stem cell derived cardiomyocytes express functional receptors for the cardiovascular peptide apelin. , 2019, , .		0
21	BS16â€…A novel fluorescent apelin ligand tracks apelin receptor internalisation. , 2019, , .		0
22	BS46â€…High content high resolution confocal imaging to characterise mutations in the apelin receptor identified in patients from the 100,000 genomes project. , 2019, , .		0
23	International Union of Basic and Clinical Pharmacology. CVII. Structure and Pharmacology of the Apelin Receptor with a Recommendation that Elabela/Toddler Is a Second Endogenous Peptide Ligand. Pharmacological Reviews, 2019, 71, 467-502.	16.0	64
24	Development and validation of an LC-MS/MS method for detection and quantification of in vivo derived metabolites of [Pyr1]apelin-13 in humans. Scientific Reports, 2019, 9, 19934.	3.3	14
25	Bile acid receptor (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide To Pharmacology CITE, 2019, 2019, .	0.2	0
26	Endothelin receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide To Pharmacology CITE, 2019, 2019, .	0.2	1
27	Trace amine receptor (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide To Pharmacology CITE, 2019, 2019, .	0.2	1
28	QRFP receptor (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide To Pharmacology CITE, 2019, 2019, .	0.2	0
29	Ghrelin receptor (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide To Pharmacology CITE, 2019, 2019, .	0.2	0
30	Apelin receptor (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide To Pharmacology CITE, 2019, 2019, .	0.2	0
31	Neuropeptide W/neuropeptide B receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide To Pharmacology CITE, 2019, 2019, .	0.2	0
32	Kisspeptin receptor (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide To Pharmacology CITE, 2019, 2019, .	0.2	0
33	Biased apelin receptor agonists for cardiovascular disease. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, SY85-1.	0.0	0
34	Elabela/Toddler Is an Endogenous Agonist of the Apelin APJ Receptor in the Adult Cardiovascular System, and Exogenous Administration of the Peptide Compensates for the Downregulation of Its Expression in Pulmonary Arterial Hypertension. Circulation, 2017, 135, 1160-1173.	1.6	183
35	[Pyr1]Apelin-13(1â€“12) Is a Biologically Active ACE2 Metabolite of the Endogenous Cardiovascular Peptide [Pyr1]Apelin-13. Frontiers in Neuroscience, 2017, 11, 92.	2.8	46
36	Cardiac action of the first G protein biased small molecule apelin agonist. Biochemical Pharmacology, 2016, 116, 63-72.	4.4	56

#	Article	IF	Citations
37	Chemerin Elicits Potent Constrictor Actions via Chemokineâ€Like Receptor 1 (CMKLR1), not Gâ€Proteinâ€Coupled Receptor 1 (GPR1), in Human and Rat Vasculature. Journal of the American Heart Association, 2016, 5, .	3.7	67
38	Endothelin. Pharmacological Reviews, 2016, 68, 357-418.	16.0	574
39	Evidence for biased agonists and antagonists at the endothelin receptors. Life Sciences, 2016, 159, 30-33.	4.3	18
40	The Concise Guide to PHARMACOLOGY 2015/16: Overview. British Journal of Pharmacology, 2015, 172, 5729-5743.	5.4	220
41	The Concise Guide to PHARMACOLOGY 2015/16: G proteinâ€coupled receptors. British Journal of Pharmacology, 2015, 172, 5744-5869.	5.4	507
42	Design, Characterization, and First-In-Human Study of the Vascular Actions of a Novel Biased Apelin Receptor Agonist. Hypertension, 2015, 65, 834-840.	2.7	131
43	Endothelin Receptors and Their Antagonists. Seminars in Nephrology, 2015, 35, 125-136.	1.6	79
44	Apelin, Elabela/Toddler, and biased agonists as novel therapeutic agents in the cardiovascular system. Trends in Pharmacological Sciences, 2015, 36, 560-567.	8.7	122
45	LGR5 Activates Noncanonical Wnt Signaling and Inhibits Aldosterone Production in the Human Adrenal. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E836-E844.	3.6	32
46	The CCR5 chemokine receptor mediates vasoconstriction and stimulates intimal hyperplasia in human vessels in vitro. Cardiovascular Research, 2014, 101, 513-521.	3.8	21
47	Akt1 Regulates Vascular Smooth Muscle Cell Apoptosis Through FoxO3a and Apaf1 and Protects Against Arterial Remodeling and Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 2421-2428.	2.4	50
48	Changes in biomechanical properties of the coronary artery wall contribute to maintained contractile responses to endothelin-1 in atherosclerosis. Life Sciences, 2014, 118, 424-429.	4.3	5
49	Endothelin@25 â€“ new agonists, antagonists, inhibitors and emerging research frontiers: <scp>IUPHAR R</scp>eview 12. British Journal of Pharmacology, 2014, 171, 5555-5572.	5.4	61
50	Modulation of endothelin receptors in the failing right ventricle of the heart and vasculature of the lung in human pulmonary arterial hypertension. Life Sciences, 2014, 118, 391-396.	4.3	13
51	Characterization of [125I]GLP-1(9-36), a novel radiolabeled analog of the major metabolite of glucagon-like peptide 1 to a receptor distinct from GLP1-R and function of the peptide in murine aorta. Life Sciences, 2014, 102, 134-138.	4.3	10
52	Endothelinâ€2, the forgotten isoform: emerging role in the cardiovascular system, ovarian development, immunology and cancer. British Journal of Pharmacology, 2013, 168, 283-295.	5.4	52
53	Intracellular Interleukin-1 Receptor 2 Binding Prevents Cleavage and Activity of Interleukin-1Î±, Controlling Necrosis-Induced Sterile Inflammation. Immunity, 2013, 38, 285-295.	14.3	172
54	Radioligand Binding Assays and Their Analysis. Methods in Molecular Biology, 2012, 897, 31-77.	0.9	86

#	Article	IF	Citations
55	Comparison of endothelin receptors in normal versus cirrhotic human liver and in the liver from endothelial cell-specific ETB knockout mice. Life Sciences, 2012, 91, 716-722.	4.3	18
56	Comparison of human ETA and ETB receptor signalling via G-protein and Î²-arrestin pathways. Life Sciences, 2012, 91, 544-549.	4.3	27
57	The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans. Life Sciences, 2012, 91, 743-748.	4.3	22
58	Defining the affinity and receptor sub-type selectivity of four classes of endothelin antagonists in clinically relevant human cardiovascular tissues. Life Sciences, 2012, 91, 681-686.	4.3	24
59	Importance of Subtype Selectivity for Endothelin Receptor Antagonists in the Human Vasculature. , 2012, , 151-172.		0
60	Chemokine receptor CCR5: from AIDS to atherosclerosis. British Journal of Pharmacology, 2011, 162, 1453-1469.	5.4	144
61	Discovery of a Competitive Apelin Receptor (APJ) Antagonist. ChemMedChem, 2011, 6, 1017-1023.	3.2	59
62	Pharmacology of Renal Endothelin Receptors. Contributions To Nephrology, 2011, 172, 1-17.	1.1	15
63	Inotropic Action of the Puberty Hormone Kisspeptin in Rat, Mouse and Human: Cardiovascular Distribution and Characteristics of the Kisspeptin Receptor. PLoS ONE, 2011, 6, e27601.	2.5	24
64	Evidence for a novel vasospastic transmitter system, neuromedin U, in the equine digital circulation. Veterinary Journal, 2010, 186, 106-109.	1.7	1
65	Positron emission tomography of [¹⁸F]â€big endothelinâ€1 reveals renal excretion but tissueâ€specific conversion to [¹⁸F]â€endothelinâ€1 in lung and liver. British Journal of Pharmacology, 2010, 159, 812-819.	5.4	15
66	Modulation of the apelin/APJ system in heart failure and atherosclerosis in man. British Journal of Pharmacology, 2010, 160, 1785-1795.	5.4	84
67	International Union of Basic and Clinical Pharmacology. LXXVII. Kisspeptin Receptor Nomenclature, Distribution, and Function. Pharmacological Reviews, 2010, 62, 565-578.	16.0	82
68	International Union of Basic and Clinical Pharmacology. LXXIV. Apelin Receptor Nomenclature, Distribution, Pharmacology, and Function. Pharmacological Reviews, 2010, 62, 331-342.	16.0	166
69	Endothelial cell-specific ET_B receptor knockout: autoradiographic and histological characterisation and crucial role in the clearance of endothelin-1This article is one of a selection of papers published in the two-part special issue entitled 20 Years of Endothelin Research.. Canadian Journal of Physiology and Pharmacology, 2010, 88, 644-651.	1.4	61
70	International Union of Pharmacology. LXXII. Recommendations for Trace Amine Receptor Nomenclature. Pharmacological Reviews, 2009, 61, 1-8.	16.0	49
71	[Pyr ¹]Apelin-13 Identified as the Predominant Apelin Isoform in the Human Heart. Hypertension, 2009, 54, 598-604.	2.7	288
72	Emerging pharmacology and physiology of neuromedin U and the structurally related peptide neuromedin S. British Journal of Pharmacology, 2009, 158, 87-103.	5.4	86

#	Article	IF	Citations
73	Immunocytochemical localization of the urotensin-II receptor, UT, to rat and human tissues: Relevance to function. Peptides, 2008, 29, 735-742.	2.4	30
74	Expression and vasoconstrictor function of anorexigenic peptides neuromedin U-25 and S in the human cardiovascular system. Cardiovascular Research, 2008, 81, 353-361.	3.8	33
75	Chronic Apoptosis of Vascular Smooth Muscle Cells Accelerates Atherosclerosis and Promotes Calcification and Medial Degeneration. Circulation Research, 2008, 102, 1529-1538.	4.5	322
76	Kisspeptins Are Novel Potent Vasoconstrictors in Humans, with a Discrete Localization of Their Receptor, G Protein-Coupled Receptor 54, to Atherosclerosis-Prone Vessels. Endocrinology, 2007, 148, 140-147.	2.8	128
77	Kisspeptins: a multifunctional peptide system with a role in reproduction, cancer and the cardiovascular system. British Journal of Pharmacology, 2007, 151, 1143-1153.	5.4	85
78	ET-A Endothelin Receptor. , 2007, , 1-8.		0
79	ET-B Endothelin Receptor. , 2007, , 1-7.		0
80	Endothelin Receptors. , 2007, , 1-3.		0
81	Apoptosis of vascular smooth muscle cells induces features of plaque vulnerability in atherosclerosis. Nature Medicine, 2006, 12, 1075-1080.	30.7	584
82	Regional heterogeneity in the haemodynamic responses to urotensin II infusion in relation to UT receptor localisation. British Journal of Pharmacology, 2006, 147, 612-621.	5.4	19
83	Characterization of the snake venom ligand [125 I]-DNP binding to natriuretic peptide receptor-A in human artery and potent DNP mediated vasodilatation. British Journal of Pharmacology, 2006, 149, 838-844.	5.4	19
84	Functional and immunocytochemical evidence for a role of ghrelin and des-octanoyl ghrelin in the regulation of vascular tone in man. Cardiovascular Research, 2006, 69, 227-235.	3.8	114
85	Novel Snake Venom Ligand Dendroaspis Natriuretic Peptide Is Selective for Natriuretic Peptide Receptor-A in Human Heart. Circulation Research, 2006, 99, 183-190.	4.5	67
86	Quantification of endothelin receptor subtypes in peripheral tissues reveals downregulation of ET(A) receptors in ET(B)-deficient mice. Experimental Biology and Medicine, 2006, 231, 741-5.	2.4	13
87	Endothelin-mediated vasoconstriction in early atherosclerosis is markedly increased in ApoE-/- mouse but prevented by atorvastatin. Experimental Biology and Medicine, 2006, 231, 806-12.	2.4	8
88	Regulation of vascular reactivity by established and emerging GPCRs. Trends in Pharmacological Sciences, 2005, 26, 448-54.	8.7	71
89	Alternative Pathway to Endothelin-Converting Enzyme for the Synthesis of Endothelin in Human Blood Vessels. Journal of Cardiovascular Pharmacology, 2004, 44, S27-S29.	1.9	13
90	Identification and cellular localisation of NPW1 (GPR7) receptors for the novel neuropeptide W-23 by [125I]-NPW radioligand binding and immunocytochemistry. Brain Research, 2004, 1017, 222-226.	2.2	49

#	Article	IF	Citations
91	Cellular distribution of immunoreactive urotensin-II in human tissues with evidence of increased expression in atherosclerosis and a greater constrictor response of small compared to large coronary arteries. Peptides, 2004, 25, 1767-1774.	2.4	106
92	Discovering orphan receptor function using human in vitro pharmacology. Current Opinion in Pharmacology, 2003, 3, 135-139.	3.5	6
93	Endothelin-Converting Enzyme Activity in Vascular Smooth Muscle Preparations In Vitro. , 2002, 206, 165-177.		7
94	Elevated systemic levels of endothelin-1 and blood pressure correlate with blunted constrictor responses and downregulation of endothelinA, but not endothelinB, receptors in an animal model of hypertension. Clinical Science, 2002, 103, 357S-362S.	4.3	16
95	G-protein-coupled receptors in human atherosclerosis: comparison of vasoconstrictors (endothelin) Tj ETQq1 1 0.784314 rgBT /Overlock Science, 2002, 103, 171S-175S.	4.3	46
96	ETA receptor antagonists inhibit intimal smooth muscle cell proliferation in human vessels. Clinical Science, 2002, 103, 184S-188S.	4.3	12
97	Discovery of recently adopted orphan receptors for apelin, urotensin II, and ghrelin identified using novel radioligands and functional role in the human cardiovascular system. Canadian Journal of Physiology and Pharmacology, 2002, 80, 369-374.	1.4	59
98	Is urotensin-II the new endothelin?. British Journal of Pharmacology, 2002, 137, 579-588.	5.4	115
99	The endothelin system in human saphenous vein graft disease. Current Opinion in Pharmacology, 2001, 1, 176-182.	3.5	10
100	[125 I]-(Pyr1)Apelin-13 is a novel radioligand for localizing the APJ orphan receptor in human and rat tissues with evidence for a vasoconstrictor role in man. British Journal of Pharmacology, 2001, 132, 1255-1260.	5.4	193
101	Vasoconstrictor activity of novel endothelin peptide, ET-1(1â€ƒ-â€ƒ31) , in human mammary and coronary arteries in vitro. British Journal of Pharmacology, 2001, 134, 1360-1366.	5.4	37
102	No Alteration in Vasoconstrictor Endothelin-B-Receptor Density or Function in Human Coronary Artery Disease. Journal of Cardiovascular Pharmacology, 2000, 36, S380-S381.	1.9	8
103	No Alteration in Vasoconstrictor Endothelin-B-Receptor Density or Function in Human Coronary Artery Disease. Journal of Cardiovascular Pharmacology, 2000, 36, S380-S381.	1.9	1
104	Comparison of the vasoconstrictor effects of the selective 5-HT1D -receptor agonist L-775,606 with the mixed 5-HT1B /1D -receptor agonist sumatriptan and 5-HT in human isolated coronary artery. British Journal of Clinical Pharmacology, 2000, 49, 126-131.	2.4	24
105	Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1. British Journal of Pharmacology, 2000, 131, 441-446.	5.4	226
106	Urotensin II: fish neuropeptide catches orphan receptor. Trends in Pharmacological Sciences, 2000, 21, 80-82.	8.7	48
107	The therapeutic potential of PD156707 and related butenolide endothelin antagonists. Expert Opinion on Investigational Drugs, 1999, 8, 71-78.	4.1	4
108	Endothelin receptor expression and pharmacology in human saphenous vein graft. British Journal of Pharmacology, 1999, 126, 443-450.	5.4	24

#	Article	IF	Citations
109	Increased response to big endothelin-1 in atherosclerotic human coronary artery: functional evidence for up-regulation of endothelin-converting enzyme activity in disease. British Journal of Pharmacology, 1998, 125, 238-240.	5.4	33
110	Comparison of the vasoconstrictor effects of rizatriptan and sumatriptan in human isolated cranial arteries: immunohistological demonstration of the involvement of 5â€HT_{1B}â€receptors. British Journal of Clinical Pharmacology, 1998, 46, 577-582.	2.4	74
111	PD156707: A Potent Antagonist of Endothelin-1 in Human Diseased Coronary Arteries and Vein Grafts. Journal of Cardiovascular Pharmacology, 1998, 31, S239-S240.	1.9	10
112	Endothelin converting enzyme (ECE) activity in human vascular smooth muscle. British Journal of Pharmacology, 1997, 122, 1647-1654.	5.4	41
113	Failure of BQ123, a more potent antagonist of sarafotoxin 6b than of endothelinâ€1, to distinguish between these agonists in binding experiments. British Journal of Pharmacology, 1996, 118, 335-342.	5.4	34
114	ET_A receptorâ€mediated constrictor responses to endothelin peptides in human blood vessels in vitro. British Journal of Pharmacology, 1995, 115, 191-197.	5.4	129
115	ETA Receptors Predominate in the Human Vasculature and Mediate Constriction. Journal of Cardiovascular Pharmacology, 1995, 26, S265-267.	1.9	53
116	Davenport and Maguire reply. Trends in Pharmacological Sciences, 1994, 15, 136-137.	8.7	11
117	Is endothelin-induced vasoconstriction mediated only by ETA receptors in humans?. Trends in Pharmacological Sciences, 1994, 15, 9-11.	8.7	129
118	[¹²⁵I]â€PD 151242: a selective radioligand for human ET_A receptors. British Journal of Pharmacology, 1994, 111, 4-6.	5.4	72
119	Vasoconstrictor endothelin receptors characterized in human renal artery and vein in vitro. British Journal of Pharmacology, 1994, 113, 49-54.	5.4	55
120	Myricerone caffeoyl ester (50???235) is a non-peptide antagonist selective for human ETA receptors. Journal of Hypertension, 1994, 12, 675???680.	0.5	9
121	Cyclic peptides as selective tachykinin antagonists. Journal of Medicinal Chemistry, 1993, 36, 2-10.	6.4	27
122	Regional effects of pertussis toxin in vivo and in vitro on GABAB receptor binding in rat brain. Neuroscience, 1993, 52, 73-81.	2.3	27
123	Age-related regional sensitivity to pertussis toxin-mediated reduction in GABAB receptor binding in rat brain. Molecular Brain Research, 1993, 18, 353-357.	2.3	13
124	Human Endothelin Receptors Characterized Using Reverse Transcriptase-Polymerase Chain Reaction, In Situ Hybridization, and Subtype-Selective Ligands BQ123 and BQ3020: Evidence for Expression of ETB Receptors in Human Vascular Smooth Muscle. Journal of Cardiovascular Pharmacology, 1993, 22, S22-S25.	1.9	114
125	L-683,877: Pharmacological profile of a novel 5-HT3 receptor antagonist. Drug Development Research, 1992, 25, 17-28.	2.9	6